Tumor-infiltrating Leukocytes Suppress Local Inflammation Via Interleukin-1 Receptor Antagonist in a Syngeneic Prostate Cancer Model.
interleukin-1 receptor antagonist
tumor microenvironment
tumor-infiltrating leukocytes
Journal
Biology
ISSN: 2079-7737
Titre abrégé: Biology (Basel)
Pays: Switzerland
ID NLM: 101587988
Informations de publication
Date de publication:
31 Mar 2020
31 Mar 2020
Historique:
received:
28
02
2020
revised:
23
03
2020
accepted:
26
03
2020
entrez:
5
4
2020
pubmed:
5
4
2020
medline:
5
4
2020
Statut:
epublish
Résumé
Several lines of evidence have demonstrated the tumor-promoting function of inflammation. Since many chemokines are important in coordinating immune cells during inflammation, monitoring intratumoral chemokines provides a way to study the tumor microenvironment. To identify tumorigenic chemokines, we compared two syngeneic mouse prostate cancer cell lines by an antibody array and quantitative reverse-transcription polymerase chain reaction (RT-PCR). The tumor microenvironment was analyzed by monitoring gene expressions in mouse tumor tissues, primary cells, and tumor-infiltrating leukocytes (TILs). We identified a group of pro-inflammatory chemokines associated with a tumorigenic transgenic adenocarcinoma mouse prostate (TRAMP)-C1 cell line. In the tumor microenvironment, the TILs secrete a natural anti-inflammatory factor, interleukin-1 receptor antagonist (IL1RN), which inhibits the functions of pro-inflammatory molecules and likely accounts for tumor type-specific anti-inflammation functions. Our results support that tumor cells recruit TILs by pro-inflammatory chemokines to establish an IL1RN-mediated anti-inflammatory environment in the syngeneic prostate cancer model.
Sections du résumé
BACKGROUND
BACKGROUND
Several lines of evidence have demonstrated the tumor-promoting function of inflammation. Since many chemokines are important in coordinating immune cells during inflammation, monitoring intratumoral chemokines provides a way to study the tumor microenvironment.
METHODS
METHODS
To identify tumorigenic chemokines, we compared two syngeneic mouse prostate cancer cell lines by an antibody array and quantitative reverse-transcription polymerase chain reaction (RT-PCR). The tumor microenvironment was analyzed by monitoring gene expressions in mouse tumor tissues, primary cells, and tumor-infiltrating leukocytes (TILs).
RESULT
RESULTS
We identified a group of pro-inflammatory chemokines associated with a tumorigenic transgenic adenocarcinoma mouse prostate (TRAMP)-C1 cell line. In the tumor microenvironment, the TILs secrete a natural anti-inflammatory factor, interleukin-1 receptor antagonist (IL1RN), which inhibits the functions of pro-inflammatory molecules and likely accounts for tumor type-specific anti-inflammation functions.
CONCLUSION
CONCLUSIONS
Our results support that tumor cells recruit TILs by pro-inflammatory chemokines to establish an IL1RN-mediated anti-inflammatory environment in the syngeneic prostate cancer model.
Identifiants
pubmed: 32244522
pii: biology9040067
doi: 10.3390/biology9040067
pmc: PMC7235745
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST107-2320-B-038-040
Organisme : Taipei Medical University
ID : TMU102-AE1-B30
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Urol. 2002 Jul;168(1):9-12
pubmed: 12050481
Cancer. 2004 Apr 1;100(7):1388-96
pubmed: 15042672
J Transl Med. 2006 Nov 10;4:48
pubmed: 17096856
Nat Med. 1999 Jul;5(7):828-31
pubmed: 10395330
Eur Urol. 2014 Jul;66(1):32-9
pubmed: 24054872
Annu Rev Immunol. 2004;22:329-60
pubmed: 15032581
Biochim Biophys Acta. 2014 Nov;1843(11):2563-2582
pubmed: 24892271
Cytokine. 1997 Jul;9(7):480-7
pubmed: 9237810
Chest. 2000 Aug;118(2):503-8
pubmed: 10936147
Front Immunol. 2015 Jun 26;6:332
pubmed: 26167165
Sci Rep. 2018 Feb 16;8(1):3135
pubmed: 29453429
Cell. 2006 Feb 10;124(3):615-29
pubmed: 16469706
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
N Engl J Med. 1984 Nov 15;311(20):1281-6
pubmed: 6436700
Cancer Res. 1997 Aug 15;57(16):3325-30
pubmed: 9269988
Genome Res. 2011 Jan;21(1):56-67
pubmed: 21036922
Sci Rep. 2018 May 16;8(1):7718
pubmed: 29769604
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
Eur J Immunol. 1993 Feb;23(2):570-3
pubmed: 8436189
Biochim Biophys Acta Mol Basis Dis. 2018 May;1864(5 Pt A):1717-1727
pubmed: 29477409
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14565-70
pubmed: 11734652
Front Pediatr. 2014 Oct 07;2:108
pubmed: 25340046
Nature. 2011 Jun 08;475(7355):222-5
pubmed: 21654748
Nature. 2010 Mar 11;464(7286):302-5
pubmed: 20220849
Annu Rev Immunol. 1998;16:27-55
pubmed: 9597123
J Immunol. 2006 Aug 15;177(4):2651-61
pubmed: 16888027
Clin Cancer Res. 2006 Feb 15;12(4):1088-96
pubmed: 16489061